Southern Medical University scientists have reported the discovery and preclinical characterization of novel microtubule-inhibiting agents being developed for the treatment of cancer. Discovery of ...
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...
The company’s lead compound ricolinostat is an oral, selective inhibitor of the microtubule-modifying enzyme histone deacetylase 6 (HDAC6). With first-in-class potential, ricolinostat is ...
An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated ... oncogene and tested for its sensitivity to inhibitors of ALK. We employed the CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback